Welcome to our dedicated page for RKLY news (Ticker: RKLY), a resource for investors and traders seeking the latest updates and insights on RKLY stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect RKLY's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of RKLY's position in the market.
Rockley Photonics Holdings Limited (NYSE: RKLY) has appointed Richard A. “Randy” Meier as president and CFO, effective immediately. Meier, previously at Intersect ENT, has extensive experience in healthcare and finance, having played a key role in its sale to Medtronic. His focus will be on enhancing Rockley's financial and commercialization strategies, aiming for efficient production ramp-up and market leadership in biosensing technologies. The leadership change is expected to drive Rockley's goals in the medtech and consumer wearables sectors.
Rockley Photonics (NYSE: RKLY) has successfully demonstrated its non-invasive, cuffless blood pressure monitoring technology, using a laser-based signal that does not rely on demographic data. An IRB-approved human study showed strong intra-subject tracking, which could enhance early diagnosis and treatment of hypertension, a precursor to serious health issues. Following promising results, Rockley plans to conduct a larger 200-participant study this fall, utilizing next-generation wearable devices.
Rockley Photonics (NYSE: RKLY) has announced an expansion of its free-living human study, which will now involve 50 participants, to assess the capabilities of its Bioptx™ biosensing band. This device aims to measure various biomarkers, including core body temperature and hydration, in real-time, promising greater accuracy than existing wearable technologies. Initial results indicated strong performance, leading to the broader study expected to conclude in Q4 2022. The findings could validate the platform's ability to enhance continuous health monitoring.
Rockley Photonics Holdings Limited (NYSE: RKLY) announced a financing of $10.0 million from holders of its Convertible Senior Secured Notes due 2026, with potential for an additional $15.0 million in financing. CEO Andrew Rickman contributed $0.5 million, raising the total to $10.5 million. This financing aims to support the commercialization of the Bioptx™ biosensing solution by year-end 2022. The details are outlined in a Current Report on Form 8-K filed on October 3, 2022.
Rockley Photonics (NYSE: RKLY) achieved a significant milestone by developing the world's first micro-transfer-printed silicon-photonics-based laser for commercial use. This technology enhances the density and reduces the size of their spectrophotometer chips, which are now the smallest for broadband infrared wavelength laser spectrometry. Additionally, it promises lower manufacturing costs and opens up new market opportunities in ultra-small wearables and advanced headsets. Importantly, this breakthrough will not affect the upcoming launch of the Bioptx™ biosensing band.
Rockley Photonics Holdings Limited (NYSE: RKLY) will participate in the Baird Newly Public Company Virtual Access Day on August 17, 2022, at 11:25 a.m. ET. Interested investors can access a live webcast and replay via the company’s investor relations page at rockleyphotonics.com. Rockley is a leader in photonics-based health monitoring and communications, developing integrated circuits and solutions for various industries, including mobile health monitoring.
Rockley Photonics (RKLY) announced a supply agreement and first commercial order for its Bioptx Baseline Band from a leading medtech company, with shipments expected in Q4 2022. The company also formed a partnership with a contract research organization to develop its biomarker sensing platform, further expanding its market opportunities. Financially, RKLY reported a revenue increase to $1.5 million for Q2 2022 but posted a net loss of $121.8 million. The company revised its 2022 revenue guidance to $5 - $10 million, eliminating all revenue from its datacom platform.
Rockley Photonics has formed a new Scientific Advisory Board (SAB)Vish Kulkarni, the board aims to support Rockley’s mission of empowering health decisions through its advanced biosensing platform, which provides non-invasive monitoring of multiple biomarkers.
Rockley Photonics (NYSE: RKLY) announced the shipment of its initial Bioptx™ biomarker sensing wristbands to medtech customers in Q4 2022. The company has received its first commercial purchase order from a global healthcare provider, marking a significant step for its biosensing technology. The wristbands enable non-invasive, continuous monitoring of multiple biomarkers, with high-volume production planned for 2023. CEO Andrew Rickman highlighted the importance of this milestone for improving patient treatment and expanding Rockley's presence in the medtech market.
Rockley Photonics (NYSE: RKLY) appointed Richard Kuntz, M.D., M.Sc., as an independent director on its board, effective August 8, 2022. Kuntz, with over 17 years at Medtronic and extensive healthcare experience, including as a professor at Harvard Medical School, brings a robust background to Rockley's leadership. His appointment expands the board to nine members, aiming to enhance the company's strategic direction in photonics-based health monitoring solutions.
FAQ
What is the market cap of RKLY (RKLY)?
